1. Home
  2. MESO vs OI Comparison

MESO vs OI Comparison

Compare MESO & OI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MESO
  • OI
  • Stock Information
  • Founded
  • MESO 2004
  • OI 1903
  • Country
  • MESO Australia
  • OI United States
  • Employees
  • MESO N/A
  • OI N/A
  • Industry
  • MESO Biotechnology: Biological Products (No Diagnostic Substances)
  • OI Containers/Packaging
  • Sector
  • MESO Health Care
  • OI Consumer Discretionary
  • Exchange
  • MESO Nasdaq
  • OI Nasdaq
  • Market Cap
  • MESO 1.7B
  • OI 1.8B
  • IPO Year
  • MESO N/A
  • OI N/A
  • Fundamental
  • Price
  • MESO $10.72
  • OI $10.95
  • Analyst Decision
  • MESO Buy
  • OI Buy
  • Analyst Count
  • MESO 4
  • OI 8
  • Target Price
  • MESO $18.00
  • OI $15.38
  • AVG Volume (30 Days)
  • MESO 240.4K
  • OI 1.6M
  • Earning Date
  • MESO 02-26-2025
  • OI 04-29-2025
  • Dividend Yield
  • MESO N/A
  • OI N/A
  • EPS Growth
  • MESO N/A
  • OI N/A
  • EPS
  • MESO N/A
  • OI N/A
  • Revenue
  • MESO $5,670,000.00
  • OI $6,531,000,000.00
  • Revenue This Year
  • MESO $228.57
  • OI $1.24
  • Revenue Next Year
  • MESO $356.77
  • OI $1.18
  • P/E Ratio
  • MESO N/A
  • OI N/A
  • Revenue Growth
  • MESO N/A
  • OI N/A
  • 52 Week Low
  • MESO $4.60
  • OI $9.23
  • 52 Week High
  • MESO $22.00
  • OI $15.72
  • Technical
  • Relative Strength Index (RSI)
  • MESO 38.38
  • OI 47.96
  • Support Level
  • MESO $10.26
  • OI $10.65
  • Resistance Level
  • MESO $11.33
  • OI $11.08
  • Average True Range (ATR)
  • MESO 0.75
  • OI 0.62
  • MACD
  • MESO 0.06
  • OI -0.00
  • Stochastic Oscillator
  • MESO 37.37
  • OI 66.67

About MESO Mesoblast Limited

Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.

About OI O-I Glass Inc.

O-I Glass is the world's largest manufacturer of glass bottles; 70% of its revenue comes from outside the United States. O-I has a leading position in key markets such as Europe, North America, and Brazil. Beer is the primary end market for O-I's glass bottles, which are also used for wine, soda, spirits, condiments, and food. O-I is looking to maintain or expand its dominant positions in Europe, North America, and South America.

Share on Social Networks: